keyword
MENU ▼
Read by QxMD icon Read
search

Carboxymaltose

keyword
https://www.readbyqxmd.com/read/28326596/systematic-review-with-network-meta-analysis-comparative-efficacy-and-tolerability-of-different-intravenous-iron-formulations-for-the-treatment-of-iron-deficiency-anaemia-in-patients-with-inflammatory-bowel-disease
#1
REVIEW
A Aksan, H Işık, H H Radeke, A Dignass, J Stein
BACKGROUND: Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalisation rates. While the best way of treating IDA in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anaemia or intolerance to oral iron compounds. AIM: To compare the efficacy and tolerability of different intravenous iron formulations used to treat IDA in IBD patients in a systematic review and Bayesian network meta-analysis (NMA), PROSPERO registration number: 42016046565...
March 21, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28289000/severe-hypophosphataemia-after-intravenous-iron-administration
#2
Gurpreet Anand, Christoph Schmid
Iron deficiency is common and can be effectively treated with parenteral iron infusion. We report a case of an iron-deficient and vitamin D-deficient woman who developed severe symptomatic hypophosphataemia following intravenous ferric carboxymaltose administration. We stress the need of increased awareness of this potential complication among physicians. Patients should be informed of this complication and instructed to report for follow-up if they experience new musculoskeletal symptoms or worsening of tiredness...
March 13, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28276325/ferric-carboxymaltose-induced-hypophosphataemia-after-kidney-transplantation
#3
V Sari, R Atiqi, E J Hoorn, A C Heijboer, T van Gelder, D A Hesselink
BACKGROUND: Ferric carboxymaltose (FCM) can induce hypophosphataemia in the general population and patients with chronic kidney disease (CKD). Less is known about the effect of FCM in the kidney transplant population. It has been suggested that fibroblast growth factor 23 (FGF-23)-mediated renal phosphate wasting may be the most likely cause of this phenomenon. In the current study, the effects of FCM on phosphate metabolism were studied in a cohort of kidney transplant recipients. METHODS: Two index patients receiving FCM are described...
March 2017: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/28210512/porphyria-cutanea-tarda-in-a-patient-with-end-stage-renal-disease-a-case-of-successful-treatment-with-deferoxamine-and-ferric-carboxymaltose
#4
Natacha Rodrigues, Fernando Caeiro, Alice Santana, Teresa Mendes, Leonor Lopes
Porphyria cutanea tarda (PCT) is a rare disease, with a strong association with hepatitis C virus. PCT is particularly problematic in end-stage renal disease patients as they have no renal excretion of porphyrins and these are poorly dialyzed. Also, conventional treatment of PCT is compromised in these patients as hydroxychloroquine is contraindicated, phlebotomies with the stipulated frequency are poorly tolerated in already anaemia-prone patients, and iron-chelating agents are less efficient in removing iron and contribute to worsening anaemia...
2017: Case Reports in Nephrology
https://www.readbyqxmd.com/read/28151394/a-fast-track-anaemia-clinic-in-the-emergency-department-cost-analysis-of-intravenous-iron-administration-for-treating-iron-deficiency-anaemia
#5
Manuel Quintana-Díaz, Raúl Muñoz-Romo, Susana Gómez-Ramírez, José Pavía, Alberto M Borobia, José A García-Erce, Manuel Muñoz
BACKGROUND: A fast-track anaemia clinic (FTAC) for the management of moderate-to-severe iron-deficiency anaemia (IDA) was established in our Emergency Department in 2010. In this FTAC, the replacement of packed red cell transfusion by ferric carboxymaltose administration was proven to be safe and effective. The aim of this study was a cost-analysis of IDA management in the FTAC, comparing this management with the previous standard care pathway consisting of packed red cell transfusion, if needed, and referral to outpatient specialised care...
January 24, 2017: Blood Transfusion, Trasfusione del Sangue
https://www.readbyqxmd.com/read/28095881/renal-function-in-patients-with-non-dialysis-chronic-kidney-disease-receiving-intravenous-ferric-carboxymaltose-an-analysis-of-the-randomized-find-ckd-trial
#6
Iain C Macdougall, Andreas H Bock, Fernando Carrera, Kai-Uwe Eckardt, Carlo Gaillard, David Van Wyck, Yvonne Meier, Sylvain Larroque, Simon D Roger
BACKGROUND: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400-600 μg/L) or lower (100-200 μg/L) ferritin values, or oral iron...
January 17, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28092401/randomized-clinical-trial-of-preoperative-oral-versus-intravenous-iron-in-anaemic-patients-with-colorectal-cancer
#7
B D Keeler, J A Simpson, O Ng, H Padmanabhan, M J Brookes, A G Acheson
BACKGROUND: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery. METHODS: Anaemic patients with non-metastatic colorectal adenocarcinoma were recruited at least 2 weeks before surgery and randomized to receive oral (ferrous sulphate) or intravenous (ferric carboxymaltose) iron...
February 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28050450/iv-ferric-carboxymaltose-vs-oral-iron-in-the-treatment-of-post-partum-iron-deficiency-anaemia
#8
Sree Chandana Damineni, Suchitra Thunga
INTRODUCTION: Iron deficiency is the most common cause of Post-partum anaemia, reported as 50-60% in India. It is primarily due to inadequate iron intake and due to peripartum blood loss. It has been associated with significant post-partum complications. Therefore, Post-partum iron deficiency warrants greater attention and higher quality care. Oral iron treatment has been considered the standard of care. However, parenteral iron treatment is expected to be advantageous in cases where oral iron therapy is not possible...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28002754/iron-nanomedicines-induce-toll-like-receptor-activation-cytokine-production-and-complement-activation
#9
Johan J F Verhoef, A Marit de Groot, Marc van Moorsel, Jeffrey Ritsema, Nataliia Beztsinna, Coen Maas, Huub Schellekens
Approximately a dozen of intravenous iron nanomedicines gained marketing authorization in the last two decades. These products are generally considered as safe, but have been associated with an increased risk for hypersensitivity-like reactions of which the underlying mechanisms are unknown. We hypothesized that iron nanomedicines can trigger the innate immune system. We hereto investigated the physico-chemical properties of ferric gluconate, iron sucrose, ferric carboxymaltose and iron isomaltoside 1000 and comparatively studied their interaction with Toll-like receptors, the complement system and peripheral blood mononuclear cells...
March 2017: Biomaterials
https://www.readbyqxmd.com/read/27971938/evaluation-of-the-economic-impact-of-ferric-carboxymaltose-use-for-the-french-national-health-insurance-and-the-french-hospitals-organization
#10
F Champs, R Augry, S Bourguignon, A Degrassat-Théas, P Paubel
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27915456/use-of-iron-sucrose-and-red-blood-cell-transfusions-in-anaemic-cancer-patients-in-france-oncofer-study
#11
Elisabeth Luporsi, Alain Toledano, Dominique Spaeth, Florian Scotté, Marc Espié, Stéphanie Perot, Ladan Duvillié, Isabelle Pithois Merli, Roland Bugat
PURPOSE: This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated cohort treated with ferric carboxymaltose (FCM) has been reported earlier. METHODS: Data of patients with a solid tumour or haematological malignancy who have received IS or an RBC transfusion during 2010 from 3 months prior (M-3) to 3 months post first treatment (M+3) were analysed...
December 3, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27907058/choice-of-high-dose-intravenous-iron-preparation-determines-hypophosphatemia-risk
#12
Benedikt Schaefer, Philipp Würtinger, Armin Finkenstedt, Vickie Braithwaite, André Viveiros, Maria Effenberger, Irene Sulzbacher, Alexander Moschen, Andrea Griesmacher, Herbert Tilg, Wolfgang Vogel, Heinz Zoller
BACKGROUND: Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM. AIM: To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort. METHODS: Electronic medical records of patients attending the University Hospital of Innsbruck were searched for the keywords ferric carboxymaltose or iron isomaltoside...
2016: PloS One
https://www.readbyqxmd.com/read/27889746/distinct-in-vitro-complement-activation-by-various-intravenous-iron-preparations
#13
Julia Cordelia Hempel, Felix Poppelaars, Mariana Gaya da Costa, Casper F M Franssen, Thomas P G de Vlaam, Mohamed R Daha, Stefan P Berger, Marc A J Seelen, Carlo A J M Gaillard
BACKGROUND: Intravenous (IV) iron preparations are widely used in the treatment of anemia in patients undergoing hemodialysis (HD). All IV iron preparations carry a risk of causing hypersensitivity reactions. However, the pathophysiological mechanism is poorly understood. We hypothesize that a relevant number of these reactions are mediated by complement activation, resulting in a pseudo-anaphylactic clinical picture known as complement activation-related pseudo allergy (CARPA). METHODS: First, the in-vitro complement-activating capacity was determined for 5 commonly used IV iron preparations using functional complement assays for the 3 pathways...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/27859495/drug-specific-hypophosphatemia-and-hypersensitivity-reactions-following-different-intravenous-iron-infusions
#14
Palle Bager, Christian L Hvas, Jens F Dahlerup
AIMS: Intravenous (IV) iron infusions have been associated with hypophosphataemia (HP) and hypersensitivity reactions (HSRs). No studies have compared the side effects of ferric carboxymaltose (FCM) with those of isomaltoside 1000 (ISM). This study aimed to describe the occurrence of HP and HSRs following the administration of either FCM or ISM. METHODS: Data on 231 outpatients treated with IV iron infusions, between November 2011 and April 2014, were collected...
November 17, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#15
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
December 13, 2016: Neurology
https://www.readbyqxmd.com/read/27852236/effects-of-intravenous-iron-on-fibroblast-growth-factor-23-fgf23-in-haemodialysis-patients-a-randomized-controlled-trial
#16
Matthew A Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M A Troster, Annette B Kent, Sukhvinder S Bansal, Iain C Macdougall, Lawrence P McMahon
BACKGROUND: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS)...
November 16, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27823710/clinical-efficacy-of-ferric-carboxymaltose-treatment-in-patients-with-restless-legs-syndrome
#17
Yong Won Cho, Richard P Allen, Christopher J Earley
OBJECTIVE: There have been three randomized, placebo-controlled, double-blind studies of intravenous iron in restless legs syndrome (RLS), with differing outcomes. The one positive study used ferric carboxymaltose (FCM) at a total dose of 1000 mg. The purpose of this study was to replicate and extend the findings from the prior FCM study. METHODS: Non-anemic, idiopathic RLS patients were enrolled in a randomized, double-blinded, placebo-controlled study and received either 1000 mg FCM or placebo as a single infusion (phase I)...
September 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27793204/high-dose-intravenously-administered-iron-versus-orally-administered-iron-in-blood-donors-with-iron-deficiency-study-protocol-for-a-randomised-controlled-trial
#18
Susanne Macher, Camilla Drexler, Ines Lindenau, Nazanin Sareban, Peter Schlenke, Karin Amrein
BACKGROUND: About 2-3 % of the population participates in blood donation programmes. Each whole blood donation or ten apheresis donations cause a loss of 200-250 mg of iron. As a result, one of the most common risks of regular blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves and higher daily requirements...
October 28, 2016: Trials
https://www.readbyqxmd.com/read/27776750/intravenous-ferric-carboxymaltose-in-children-with-iron-deficiency-anemia-who-respond-poorly-to-oral-iron
#19
Jacquelyn M Powers, Mark Shamoun, Timothy L McCavit, Leah Adix, George R Buchanan
OBJECTIVE: To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA). STUDY DESIGN: In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record. RESULTS: A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13...
January 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/27774269/rationale-and-design-of-a-pilot-randomized-controlled-trial-to-assess-the-role-of-intravenous-ferric-carboxymaltose-in-asian-patients-with-heart-failure-practice-asia-hf
#20
Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Bee Choo Tai, Carolyn S P Lam
AIMS: Iron deficiency (ID) is highly prevalent in patients with heart failure (HF) worldwide regardless of haemoglobin levels. Results from therapeutic trials of intermittently dosed intravenous (i.v.) iron are promising in the ambulatory Caucasian population with HF with reduced left ventricular ejection fraction, although evidence is scarce in Asia. The Pilot Randomized Controlled Trial to Assess the Role of Intravenous Ferric Carboxymaltose in Asian Patients with Heart Failure aims to assess the effect of single-dose i...
June 2016: ESC Heart Failure
keyword
keyword
16762
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"